Seattle Genetics

Bruce J. Seeley has been named executive vice president, commercial at Seattle Genetics. Mr. Seeley brings more than 18 years of experience in oncology drug marketing and sales to the company, most recently from Genentech BioOncology. The company also promoted Kirk D. Schumacher to vice president, legal affairs and compliance, and general counsel.

“Bruce will lead our efforts to build Seattle Genetics’ marketing and sales functions as we position the company for commercial operations, including the planned 2011 product launch of brentuximab vedotin (SGN-35),” said Clay B. Siegall, Ph.D., president and chief executive officer. “His depth of experience in the commercialization of oncology drugs, including two of the most important therapies for the treatment of cancer, Herceptin and Taxotere, will be a tremendous asset to the company.”

Dr. Siegall added, “Kirk Schumacher has been instrumental at Seattle Genetics, including his contributions to several strategic collaborations and equity financings, and his oversight of our legal affairs. Bruce and Kirk will play key leadership roles as Seattle Genetics continues to execute on its corporate goals.”

Mr. Seeley previously worked at Genentech, most recently as senior director for Herceptin and T-DM1 marketing. His responsibilities included development and implementation of marketing and launch strategies, including product differentiation, pricing, distribution, medical education and promotion. Before that, he spent four years at Aventis Pharma in increasing roles of responsibility, including head of new product commercialization and licensing, global marketing, oncology. While at Aventis, he managed the global marketing activities for Taxotere. Mr. Seeley also held various marketing and sales positions at Rhone-Poulenc Rorer and Bristol-Myers Squibb. He received a Bachelor of Arts in Sociology from the University of California at Los Angeles.